Gastroenterology in 2025 entered a new phase of targeted and metabolic care. IL-23 inhibitors expanded treatment sequencing in inflammatory bowel disease, while the first approved therapy for MASH shifted hepatology from surveillance to active intervention. Alongside these advances, AI-enabled pathology began reshaping how liver disease therapies a
618 Reached1 Comments
Single-incision Laparoscopy for Gastrostomy
410 Reached2 Comments1 Likes
Intestinal Obstruction and Ileocolic Fistula due to Gossypiboma
863 Reached30 Comments15 Likes
Woman with Complaint of Spontaneous Massive Rectal Prolapse
1867 Reached17 Comments9 Likes
Study evaluating Effectiveness of Bacillus clausii for Treatment of Rotavirus Infection
1303 Reached4 Comments6 Likes
Psychological Manifestations Of IBS
662 Reached1 Comments1 Likes